Therapeutics for Vancomycin-Resistant Enterococcal Bloodstream Infections-Reference-Cited by-同舟云学术

Therapeutics for Vancomycin-Resistant Enterococcal Bloodstream Infections

Published:2023-06-21 Issue:2 Volume:36 Page:
ISSN:0893-8512
Container-title:Clinical Microbiology Reviews
language:en
Short-container-title:Clin Microbiol Rev

Author:

Cairns Kelly A.¹²^ORCID,Udy Andrew A.³⁴^ORCID,Peel Trisha N.¹^ORCID,Abbott Iain J.¹⁵^ORCID,Dooley Michael J.²⁶,Peleg Anton Y.¹⁷⁸^ORCID

Affiliation:

1. Department of Infectious Diseases, The Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia

2. Pharmacy Department, Alfred Health, Melbourne, Victoria, Australia

3. Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia

4. Department of Intensive Care and Hyperbaric Medicine, The Alfred, Melbourne, Victoria, Australia

5. Microbiology Unit, Alfred Health, Melbourne, Victoria, Australia

6. Centre for Medicines Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia

7. Infection Program, Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, Victoria, Australia

8. Centre to Impact AMR, Monash University, Clayton, Victoria, Australia

Abstract

Vancomycin-resistant enterococci (VRE) are common causes of bloodstream infections (BSIs) with high morbidity and mortality rates. They are pathogens of global concern with a limited treatment pipeline.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Microbiology (medical),Public Health, Environmental and Occupational Health,General Immunology and Microbiology,Epidemiology

Link

https://journals.asm.org/doi/pdf/10.1128/cmr.00059-22

Reference283 articles.

1. One Health in hospitals: how understanding the dynamics of people, animals, and the hospital built-environment can be used to better inform interventions for antimicrobial-resistant gram-positive infections

2. Australian Government. 2015. Responding to the threat of antimicrobial resistance, Australia’s first national antimicrobial resistance strategy 2015–2019. Commonwealth of Australia, Canberra, ACT, Australia.

3. CDC. 2019. Antibiotic resistance threats in the United States, 2019. US Department of Health and Human Services, CDC, Atlanta, GA. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf.

4. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

5. The COVID-19 pandemic: a threat to antimicrobial resistance containment

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vancomycin-resistant Enterococcus faecium in Japan, 2007–2015: a molecular epidemiology analysis focused on examining strain characteristics over time;Microbiology Spectrum;2024-01-11

2. Thiazolopyrimidinone Derivative H5–23 Enhances Daptomycin Activity against Linezolid-Resistant Enterococcus faecalis by Disrupting the Cell Membrane;ACS Infectious Diseases;2023-11-28

3. Antimicrobial and antibiofilm effects of essential fatty acids against clinically isolated vancomycin-resistant Enterococcus faecium;Frontiers in Cellular and Infection Microbiology;2023-09-29

4. Probiotics and Their Bioproducts: A Promising Approach for Targeting Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus;Microorganisms;2023-09-25